Siemens involved bribery business administration has investigated

According to foreign media Reuters, three sources familiar with the situation revealed to Reuters recently that Chinese regulators investigated Siemens last year to find out whether the German giant’s medical department and its distributors bribed hospitals to purchase certain medical devices. On expensive disposable products.

Reuters said that it revealed to them that two of the three sources had direct knowledge of the investigation. They all asked not to be named. The third source and Siemens teamed up closely with the medical team in China and learned about the investigation. According to sources disclosed by Reuters, the reliability of this news is extremely high.

In 2013, GlaxoSmithKline took bribery doctors and experts and was jointly investigated by the industry and commerce departments and the Ministry of Public Security. The responsible persons of related companies were taken away by the Public Security Bureau. As a result, the domestic pharmaceutical industry started an anti-corruption climax. Two years later, the international medical device giant Siemens was investigated again, or it may set off another round of climax for the medical device industry.

A Reuters report quoted a person familiar with the matter as saying that the Siemens investigation involved about 1,000 hospitals, which may also be a signal that Chinese regulators are investigating further manufacturers of medical equipment.

According to informed sources, the China Administration for Industry and Commerce accused Siemens and its distributors of providing medical equipment free of charge in exchange for the exclusive use of chemical reagents developed by Siemens on this equipment. The behavior of the company violated China’s “Unfair Competition Law”. "Provisions.

According to analysis, Siemens investigated or with the current Chinese government is urging hospitals to use more domestically produced medical equipment and reduce dependence on imported products. It is reported that imported medical products account for about three quarters of China's $34 billion medical equipment market.

However, Seibu Lan believes that it may not be entirely unexpected that equipment companies have been involved in the investigation under the condition that medical anti-corruption has been further upgraded.

Resolving expensive medical treatment has always been the focus of current medical reforms. Looking at the policy trends introduced by the State Council and the Provincial Health Planning Commissions, it has been fully recognized that you are paying attention to your medical expenses. In addition to lowering the price of drugs, many provinces have undergone medical reforms. In the policy, an important aspect is to check the price, and the bidding for high-value consumables and equipment has also become an industry trend.

On April 29, Premier Li Keqiang made important instructions for the 2015 tele-phone conference to deepen the reform of the medical and health system. Vice Premier Liu Yandong also made an important speech.

The two prime ministers are demanding that they take the courage to test the depths of the river and dare to enter the new dangers of rapid medical reform. The elimination of the old pattern of interests will in particular require strengthening anti-corruption investigations to create a favorable policy environment for the smooth implementation of medical reform.

In 2014, more than 20 hospital directors across the country were investigated by the Commission for Discipline Inspection or entered judicial proceedings. Hainan, Anhui, Sichuan, Jiangxi and other places also investigated a number of corruption cases in the health system. In January 2015, the Central Commission for Discipline Inspection released 58 cases of violations of the health plan system.

In addition, the National Health and Family Planning Commission has also decided to carry out a three-year inspection activity since 2015. The target is 41 hospitals, including Qilu Hospital of Shandong University and Zhongshan Hospital affiliated to Fudan University. The purpose is to find solutions to the deep problems of large-scale hospitals.

Looking at the anti-corruption of the pharmaceutical industry, China is not against the individual anti-corruption of multinational pharmaceutical companies. The entire pharmaceutical industry has generally entered the surveyed sequence. Presumably this is also true for the medical device industry.

Medical device manufacturers, agents, hospital presidents, chiefs of equipment divisions, key personnel at both ends of supply and demand for medical device sales have formed an implicit high-risk interest chain. In today's society, "the use of medical equipment does not become a doctor", the role of medical devices in the medical field and the corruption they cause are equally compelling.

In 2013, GlaxoSmithKline was investigated by the General Administration of Industry and Commerce. According to media reports at the time, hundreds of hospitals were involved. Now foreign media reported that thousands of hospitals have been involved. If Reuters’s report is true, this is probably the case. A major case of at least comparable shoulder GlaxoSmithKline.